+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology

Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology

Nederlands Tijdschrift Voor Geneeskunde 144(32): 1520-1528

Positron emission tomography with fluoro-18-deoxyglucose as tracer molecule (FDG-PET) is a relatively new imaging technique used in oncology to study tumour metabolism in vivo. Both qualitative and quantitative data obtained by PET provide unique information to the clinician and may guide the therapeutic approach in selected patients, where conventional diagnostic tests like CT or MRI yield equivocal results. According to the experience obtained in the Vrije Universiteit Medical Centre in Amsterdam, the additional value of FDG-PET can be explained by the sensitivity and the specificity of the technique, combined with the visualization of the whole body. FDG-PET may reveal metastases and tumour tissue may be differentiated from scar tissue and necrosis. PET is expensive and its effects on patient outcome has yet to be established.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 045170878

Download citation: RISBibTeXText

PMID: 10949634

Related references

Role of 18-fluoro-2-deoxyglucose positron emission tomography in detecting acute inflammatory lesions of non-bacterial osteitis in patients with a fever of unknown origin: A comparative study of 18-fluoro-2-deoxyglucose positron emission tomography, bone scan, and magnetic resonance imaging. Modern Rheumatology 28(6): 1058-1062, 2018

Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. European Heart Journal 22(18): 1691-1701, 2001

The added value of [18F]-fluoro-D-deoxyglucose positron emission tomography in screening for temporal lobe epilepsy surgery. Epilepsia 48(11): 2121-2129, 2007

Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography Computed Tomography in the Evaluation of Gastrointestinal Malignancies. Current Medical Imaging Reviews 4(4): 255-269, 2008

6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Molecular Imaging and Biology 7(4): 257-261, 2005

Second primary malignancy of breast in a patient of gastrointestinal stromal tumor presenting as fluoro-deoxyglucose-avid breast incidentaloma in fluoro-deoxyglucose-positron emission tomography. Journal of Cancer Research and Therapeutics 7(3): 387-389, 2012

Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clinical Infectious Diseases 32(2): 191-196, 2001

Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. European Journal of Clinical Microbiology and Infectious Diseases 21(4): 247-257, 2002

A kinetic comparison of [18F]2-fluoro-2-deoxyglucose and [18F]2-fluoro-2-deoxymannose using positron emission tomography. Nuclear Medicine and Biology 21(6): 857-863, 1994

Cerebral fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI, and clinical observations in a patient with infantile GM1 gangliosidosis. Brain and Development 21(8): 559-562, 1999

Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology 54(5): 900-904, 1999

Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 42(1): 89-92, 2012

Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose (FDG) in patients with suspicion of recurrent laryngeal carcinoma. Acta Otorrinolaringologica Espanola 57(3): 134-139, 2006

F-18-2-fluoro-2-deoxyglucose positron emission tomography compared to technetium-99m hexakis-2-methoxyisobutyl isonitrile single photon emission chest tomography in the diagnosis of indeterminate lung lesions. Respiration; International Review of Thoracic Diseases 80(6): 524-533, 2010

Advantages of L-3-[(18)F] fluoro-alpha-methyl tyrosine over 2-[(18)F]-fluoro-2-deoxyglucose in detecting liver metastasis during positron emission tomography scan. Springerplus 5: 618, 2016